Phentermine/Topiramate Extended-Release Capsules Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 3.75 mg/23 mg, 7.5 mg/46 mg, and 15 mg/92 mg
Reference Brands: Qsymia(US & EU)
Category:
Weight Loss drugs
Phentermine/topiramate extended-release capsules suppress appetite by combining phentermine’s stimulant effects with topiramate’s appetite-suppressant properties. This combination supports significant weight loss, reduces hunger, improves metabolic health, and enhances cardiovascular outcomes. Benefits include sustained weight reduction, appetite control, improved energy, and better overall health in obesity management worldwide.
Phentermine/Topiramate Extended-Release Capsules is available in Capsules
and strengths such as 3.75 mg/23 mg, 7.5 mg/46 mg, and 15 mg/92 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Phentermine/Topiramate Extended-Release Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Phentermine/Topiramate Extended-Release Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Phentermine/Topiramate extended-release capsules, marketed as Qsymia, are approved in the US by the FDA and in the EU via EMA for weight management in obese adults. Regulatory approval requires dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For dossier preparation, regulatory pathways, and market access guidance, visit PharmaTradz. Proper adherence to regional regulations supports swift approval, safe administration, and worldwide availability, helping patients achieve effective weight loss and health improvements through high-quality extended-release capsules supported by regional authorities.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing